Internal Medicine, Endocrinology, Diabetes, & Metabolism · Ridgewood, NJ
NPI
1912065442
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
947 Linwood Ave, Suite 1w
Ridgewood, NJ, 07450
Phone (201) 444-5552
Groups this clinician bills Medicare through
Medicare paid, 2024
$330K
10,777 services
Medicare patients, 2024
1,002
Average age 75
Drug cost, 2024
$2.9M
7,211 prescriptions
Company payments, 2025
$1,216
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adam S Kelman was code J0897 (injection, denosumab, 1 mg), 5,460 times for 53 patients. In total Adam S Kelman billed 10,777 services in 29 codes, and Medicare paid $330K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-06-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,460 | 53 | $20.53 | $112K |
| 99214 Office E&M - Established | Office | 857 | 586 | $103.63 | $89K |
| 36415 Venipuncture Blood Collection | Office | 723 | 514 | $8.60 | $6,220 |
| 99213 Office E&M - Established | Office | 254 | 220 | $72.68 | $18K |
| 76536 Ultrasound - Nonspecific | Office | 208 | 198 | $100.29 | $21K |
| 99232 Hospital E&M - Subsequent | Facility | 205 | 90 | $70.56 | $14K |
| 95251 Test - Miscellaneous | Office | 172 | 87 | $27.96 | $4,808 |
| 96372 Injection Administration | Office | 133 | 63 | $11.99 | $1,595 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 50 | 49 | $14.38 | $719 |
| 99215 Office E&M - Established | Office | 42 | 37 | $161.51 | $6,783 |
| 82947 Clinical Chemistry | Office | 27 | 23 | $3.85 | $104 |
| 99222 Hospital E&M - Initial | Facility | 27 | 27 | $118.06 | $3,188 |
| 10005 Other Organ Systems | Office | 20 | 17 | $114.96 | $2,299 |
By year: 2022 $280K for 7,682 services; 2023 $278K for 7,423 services; 2024 $330K for 10,777 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 723 | 514 | $8.60 | $6,220 |
| 82947 Clinical Chemistry | 27 | 23 | $3.85 | $104 |
Medicare prescription drug claims, 2024
In 2024, the drug Adam S Kelman prescribed most often to Medicare patients was Levothyroxine Sodium, with 953 prescriptions and refills. In total Adam S Kelman wrote 7,211 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 953 | 2,691 | 264 | $12K |
| Metformin Hcl Generic | 416 | 1,181 | 124 | $4,289 |
| Glimepiride Generic | 381 | 1,076 | 102 | $4,834 |
| Jardiance Empagliflozin | 368 | 681 | 72 | $381K |
| Ozempic Semaglutide | 344 | 588 | 70 | $547K |
| Synthroid Levothyroxine Sodium | 340 | 954 | 87 | $31K |
| Metformin Hcl Er Metformin Hcl | 317 | 887 | 87 | $3,780 |
| Januvia Sitagliptin Phosphate | 245 | 533 | 56 | $283K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 207 | 504 | 65 | $31K |
| Farxiga Dapagliflozin Propanediol | 206 | 440 | 45 | $241K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 191 | 513 | 74 | $22K |
| Atorvastatin Calcium Generic | 159 | 443 | 43 | $1,493 |
| Mounjaro Tirzepatide | 159 | 230 | 34 | $239K |
| Glipizide Er Glipizide | 157 | 426 | 47 | $3,364 |
| Humalog Kwikpen U-100 Insulin Lispro | 149 | 381 | 55 | $44K |
Brand drugs: 3,517 claims; generic drugs: 3,278 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adam S Kelman $1,216 ($1,216 in general payments such as food, travel and fees) from 15 companies. The largest payer was Novo Nordisk Inc with $250.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 10 | $250 |
| Sanofi-Aventis U.S. LLC SNY | 8 | $185 |
| Sequel Med Tech, LLC | 1 | $159 |
| Fresenius Kabi USA, LLC | 1 | $125 |
| Corcept Therapeutics CORT | 5 | $99.57 |
| Lilly USA, LLC LLY | 5 | $89.2 |
| Insulet Corporation PODD | 3 | $72.36 |
| Abbott Laboratories ABT | 3 | $64.76 |
| Ascensia Diabetes Care Us Inc. | 2 | $45.41 |
| Amgen Inc. AMGN | 2 | $36.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.